Analysts at Needham & Company LLC started coverage on shares of Vascular Solutions Inc. (NASDAQ:VASC) in a note issued to investors on Thursday. The firm set a “buy” rating on the medical device company’s stock.

A number of other equities research analysts have also recently commented on VASC. Piper Jaffray Cos. increased their target price on shares of Vascular Solutions from $45.00 to $49.00 and gave the company an “overweight” rating in a research report on Tuesday, July 26th. Zacks Investment Research cut shares of Vascular Solutions from a “buy” rating to a “hold” rating in a research report on Wednesday, June 29th. TheStreet upgraded shares of Vascular Solutions from a “hold” rating to a “buy” rating in a research report on Monday, July 25th. Canaccord Genuity reiterated a “buy” rating on shares of Vascular Solutions in a research report on Wednesday, August 10th. Finally, Sidoti cut shares of Vascular Solutions from a “buy” rating to a “neutral” rating and set a $47.00 price objective for the company. in a research report on Tuesday, July 12th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Vascular Solutions has an average rating of “Buy” and an average price target of $47.38.

Shares of Vascular Solutions (NASDAQ:VASC) opened at 47.11 on Thursday. Vascular Solutions has a 52-week low of $24.34 and a 52-week high of $50.72. The stock has a market capitalization of $824.00 million, a PE ratio of 87.24 and a beta of 0.54. The firm has a 50-day moving average of $48.46 and a 200 day moving average of $41.41.

Vascular Solutions (NASDAQ:VASC) last issued its earnings results on Monday, July 25th. The medical device company reported $0.33 EPS for the quarter, beating the Zacks’ consensus estimate of $0.30 by $0.03. The business earned $41.20 million during the quarter, compared to analysts’ expectations of $41.40 million. Vascular Solutions had a net margin of 6.22% and a return on equity of 16.32%. The company’s quarterly revenue was up 9.7% compared to the same quarter last year. During the same period in the prior year, the business earned $0.29 earnings per share. Equities research analysts forecast that Vascular Solutions will post $1.24 EPS for the current fiscal year.

In other Vascular Solutions news, CEO Howard Root sold 40,000 shares of Vascular Solutions stock in a transaction dated Wednesday, July 27th. The shares were sold at an average price of $45.11, for a total transaction of $1,804,400.00. Following the completion of the sale, the chief executive officer now directly owns 347,840 shares in the company, valued at $15,691,062.40. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP William Rutstein sold 10,011 shares of Vascular Solutions stock in a transaction dated Wednesday, July 27th. The shares were sold at an average price of $46.26, for a total transaction of $463,108.86. The disclosure for this sale can be found here. Corporate insiders own 6.90% of the company’s stock.

Several large investors have recently made changes to their positions in the stock. Prudential Financial Inc. boosted its stake in shares of Vascular Solutions by 3.7% in the first quarter. Prudential Financial Inc. now owns 42,347 shares of the medical device company’s stock worth $1,378,000 after buying an additional 1,500 shares in the last quarter. Mckinley Capital Management LLC Delaware bought a new stake in shares of Vascular Solutions during the first quarter worth $2,590,000. Menta Capital LLC bought a new stake in shares of Vascular Solutions during the first quarter worth $320,000. Ruffer LLP boosted its stake in shares of Vascular Solutions by 22.2% in the first quarter. Ruffer LLP now owns 55,000 shares of the medical device company’s stock worth $1,790,000 after buying an additional 10,000 shares in the last quarter. Finally, Uniplan Investment Counsel Inc. boosted its stake in shares of Vascular Solutions by 0.4% in the first quarter. Uniplan Investment Counsel Inc. now owns 117,429 shares of the medical device company’s stock worth $3,820,000 after buying an additional 422 shares in the last quarter. Institutional investors and hedge funds own 82.08% of the company’s stock.

About Vascular Solutions

Vascular Solutions, Inc is a medical device company focused on bringing clinically advanced solutions to the market for treating coronary and peripheral vascular disease. The Company’s product line consists of devices and services that are sold to interventional cardiologists, interventional radiologists, electrophysiologists and vein practices around the world.

5 Day Chart for NASDAQ:VASC

Receive News & Stock Ratings for Vascular Solutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Solutions Inc. and related stocks with our FREE daily email newsletter.